ALAVERT D-12 HOUR OTC
Generic Name and Formulations:
Loratadine 5mg, pseudoephedrine sulfate 120mg; ext-rel tabs.
Indications for ALAVERT D-12 HOUR:
Seasonal allergic rhinitis with nasal congestion.
Swallow whole. 1 tab every 12 hrs.
Narrow-angle glaucoma. Urinary retention. Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hepatic or renal impairment. Hypertension. Ischemic heart disease. Increased intraocular pressure. Thyroid disease. GI or GU obstruction. Seizures. Diabetes. Pregnancy (Cat.B). Nursing mothers: not recommended.
See Contraindications. Pseudoephedrine: Antagonizes antihypertensives. Increased ectopic pacemaker activity with digitalis.
Antihistamine + sympathomimetic.
Dry mouth, insomnia, somnolence, nervousness, dizziness, dyspepsia, pharyngitis, anorexia, bronchospasm.
Loratadine: Hepatic (CYP3A4, 2D6); Pseudoephedrine: incompletely metabolized (less than 1%).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|